secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-06-22T12:10:21+00:00
Accession:  0001213900-26-070382
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity announces Trial-in-Progress poster for Phase 2 stenoparib at ESMO Gynaecological Cancers Congress 2026
--------------------------------------------------------------------------------

- Poster outlines Phase 2 trial of stenoparib (dual PARP/WNT inhibitor) for platinum-resistant ovarian cancer.
- Presented by Principal Investigator Dr. Kathleen N. Moore, expert in advanced ovarian cancer.
- No new clinical data reported; Trial-in-Progress design describes study rationale and design only.
- Conference held June 17–19, 2026 in Copenhagen, Denmark; poster displayed June 18, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/0001213900-26-070382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/ea0295409-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-070382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer